Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPD10558 in Statin-Intolerant Primary Hypercholesterolemia
NCT01279590Phase 2Completed
- Sponsor
- Furiex Pharmaceuticals
- Start
- Mar 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RBx 10558 in hypercholesterolemia (3 arms), sponsored by Furiex Pharmaceuticals. Primary endpoint: Incidence of stopping treatment with double-blinded study drug due to statin-associated myalgia at 12 weeks. Started Mar 2011; status: completed.
02
Drugs
RBx 10558
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01279590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01279590.